Dynegy Inc. (DYN) News
Dynegy Inc. (DYN) Recent IPO
Today's Latest Price: $18.40 USD
Updated Jan 27 6:55pm
Add DYN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
StocksNews Articles for DYN
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DYN News From Around the Web
Below are the latest news stories about Dyne Therapeutics Inc that investors may wish to consider to help them evaluate DYN as an investment opportunity.
Dyne Therapeutics prices $168M share offeringDyne Therapeutics (DYN) has priced its public offering of 6M common shares at $28.00/share, for expected gross proceeds of ~$168M.Underwriters' over-allotment is an additional 900K shares.Closing date is January 25.... |
Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares PlummetMidway through trading opening Thursday, the Dow traded down 0.12% to 31,150.37 while the NASDAQ rose 0.37% to 13,507.06. The S&P also fell, dropping … |
EFFECT - Dyne Therapeutics, Inc. (0001818794) (Filer) - Stocks News FeedAccepted 2021-01-21 00:16:06 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2021-01-20 Registration Form S-1 Document Format Files Mailing Address 830 WINTER STREET WALTHAM MA 02451 Business Address 830 WINTER STREET WALTHAM MA 02451 (781) 786-8230 Dyne Therapeutics, Inc. (Filer) CIK: 0001818794 (see all company… Read More »EFFECT – Dyne Therapeutics, Inc. (0001818794) (Filer) |
Dyne Therapeutics Announces Pricing of $168 Million Public Offering - Stocks News FeedWALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $28.00 per share. In… Read More »Dyne Therapeutics Announces Pricing of $168 Million Public Offering |
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines OperationsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ... |
The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements ContinueHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X Genomics Inc (NASDAQ: TXG ) AbbVie Inc (NYSE: (ABBV) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) (reacted to the company's preliminary fourth-quarter results) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Biodesix Inc (NASDAQ: BDSX ) C4 Therapeutics Inc (NASDAQ: CCCC ) CareDx Inc (NASDAQ: CDNA ) (announced preliminary fourth-quarter results) Celsius Holdings, Inc. (NASDAQ: CELH ) Chimerix Inc (NASDAQ: CMRX ) Curis, Inc. (NASDAQ: CRIS ) Dyne Therapeutics Inc (NASDAQ: DYN ) (announced positive preclinical data from its myotonic dystrophy type 1 program) Edap Tms SA (NASDAQ:... |
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study\- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -\- Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -WALTHAM, Mass., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data from its myotonic dystrophy type 1 (DM1) program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.Dyne’s FORCE™ platform leverages the importance of transferrin 1 receptor, TfR1, in muscle biology as the foundation for its novel approach. TfR1, which is hi... |
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/investors-and-media and a replay will be accessible for 90 days following the presentation.About Dyne TherapeuticsDyne Therapeutics is building a leading muscle disease company focused... |
Cerevance Appoints David Lubner to Board of DirectorsLife sciences industry veteran brings more than 25 years of financial and operational experienceBOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors. Mr. Lubner most recently served as executive vice president and chief financial officer of Ra Pharma, which was acquired by UCB in April of this year. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Ve... |
Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead… |